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ABSTRACT
TP53 has been implicated in regulation of the cell cycle, DNA repair,
and apoptosis. We studied, in primary breast tumors through direct
cDNA sequencing of exons 2–11, whether TP53 gene mutations can predict
response in patients with advanced disease to either first-line tamoxifen
therapy (202 patients, of whom 55% responded) or up-front (poly)che-
motherapy (41 patients, of whom 46% responded). TP53 mutations were
detected in 90 of 243 (37%) tumors, and one-fourth of these mutations
resulted in a premature termination of the protein. The mutations were
observed in 32% (65 of 202) of the primary tumors of tamoxifen-treated
patients and in 61% (25 of 41) of the primary tumors of the chemotherapy
patients. TP53 mutation was significantly associated with a poor response
to tamoxifen [31% versus 66%; odds ratio (OR), 0.22; 95% confidence
interval (CI), 0.12–0.42; P < 0.0001]. Patients with TP53 gene mutations
in codons that directly contact DNA or with mutations in the zinc-binding
domain loop L3 showed the lowest response to tamoxifen (18% and 15%
response rates, respectively). TP53 mutations were related, although not
significantly, to a poor response to up-front chemotherapy (36% versus
63%; OR, 0.34; 95% CI, 0.09–1.24). In multivariate analysis for response
including the classical parameters age and menopausal status, disease-free
interval, dominant site of relapse, and levels of estrogen receptor and
progesterone receptor, TP53 mutation was a significant predictor of poor
response in the tamoxifen-treated group (OR, 0.29; 95% CI, 0.13–0.63;
P 5 0.0014). TP53-mutated and estrogen receptor-negative (<10 fmol/mg
protein) tumors appeared to be the most resistant phenotype. Interest-
ingly, the response of patients with TP53 mutations to chemotherapy after
tamoxifen was not worse than that of patients without these mutations
(50% versus 42%; OR, 1.35, nonsignificant). The median progression-free
survival after systemic treatment was shorter for patients with a TP53
mutation than for patients with wild-type TP53 (6.6 and 0.6 months less
for tamoxifen and up-front chemotherapy, respectively). In conclusion,
TP53 gene mutation of the primary tumor is helpful in predicting the
response of patients with metastatic breast disease to tamoxifen therapy.
The type of mutation and its biological function should be considered in
the analyses of the predictive value of TP53.
INTRODUCTION
TP53, a tumor suppressor gene, has been shown to have prognostic
value in patients with breast cancer. A few studies with conflicting
results on its predictive value have been published. Endocrine treat-
ment and chemotherapy improve the survival of women with (primary
or advanced) breast cancer. The antiestrogen tamoxifen is one of the
major compounds used for the endocrine treatment of breast cancer. It
is effective in about one-third of all patients with metastatic disease
and in about 50% of those breast cancer patients that are ER3 positive.
Like chemotherapeutic agents, tamoxifen may cause DNA damage
(1). TP53, by regulating response to DNA damage, is a key element
in DNA repair. This tumor suppressor gene has also been implicated
in the regulation of normal cell growth and division, gene transcrip-
tion, genomic stability, apoptosis, and senescence. Mutations in the
TP53 gene (also known as P53) are the most frequent genetic changes
found in human breast cancer. Mutation is often accompanied by
deletion of the second allele, resulting in the elimination of wild-type
TP53 activity. P53 protein accumulation, which often results from
TP53 gene mutation, can be measured with immunological tech-
niques, i.e., IHC or LIA/ELISAs on tumor extracts.
In two studies on patients with metastatic breast cancer (including
92 and 205 patients, respectively), no significant relation between
immunohistochemically assessed P53 expression and response to en-
docrine treatment was observed (2, 3), whereas in another study (on
17 patients), P53 overexpression was associated with a poor response
to endocrine therapy (4). Recently, we have shown a significant
relation between P53 accumulation, as measured by a LIA, and poor
response to tamoxifen therapy in a series of 401 patients (5). More-
over, the existing data on TP53 do not clarify its capability to predict
resistance to chemotherapy for advanced or recurrent breast cancer
(6–9). Furthermore, the data on its predictive role in the adjuvant
setting are conflicting as well (10–16). Studies on the predictive value
of TP53 are hampered by a number of methodological issues includ-
ing immunological versus molecular biological analyses, use of dif-
ferent cutoff levels in the immunohistochemical analyses, or selection
of patient groups.
About 20% of the TP53 gene mutations do not result in p53 protein
accumulation, whereas, on the other hand, p53 accumulation may also
occur without a gene mutation. Therefore we have studied TP53 gene
mutations in a relatively large series of 243 patients with advanced
disease. Analysis of the various mutations allowed us to investigate
the biological significance of particular mutations, which may even-
tually aid in selecting those aberrations that could be of predictive
value in breast cancer. We show that TP53 gene mutations predict a
poor response to first-line tamoxifen therapy and probably to chem-
otherapy in advanced breast cancer. In an exploratory subset analysis,
we also observed that mutations in one zinc-binding domain, i.e., loop
L3, or in codons that directly contact DNA were related with an even
poorer response to tamoxifen.
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PATIENTS AND METHODS
Assays of Cell Biological Factors
Sequence-based Analysis of TP53. cDNA-based sequencing was used
essentially as described by Bergh et al. (14), Sjo¨gren et al. (17), Kressner et al.
(19) and Falette et al. (20). Frozen untreated primary tumor samples were
verified histologically for the presence of tumor cells, and only those samples
containing more than 20% tumor cells were included in our study. mRNA was
prepared from the frozen samples under stringent conditions to avoid degra-
dation and contamination, and cDNA was generated. TP53 was amplified from
the tumor cDNA by PCR using four sets of overlapping primers (one primer
in each pair was biotin-labeled) to cover the complete protein coding region
(exons 2–11) of the TP53 cDNA. Solid-phase sequencing was carried out using
Autoload solid-phase sequencing combs and T7 DNA polymerase (Amersham
Pharmacia Biotech). Samples were analyzed on an automated laser fluores-
cence DNA sequencer (Amersham Pharmacia Biotech). Sequence gels and
sequences were evaluated with Sequence Evaluator and Mutation Analyzer
software (Amersham Pharmacia Biotech). All mutations were confirmed by
reamplifying the relevant cDNAs and sequencing the new PCR products.
Assays of ER and PgR. ER and PgR levels were determined in cytoplas-
mic extracts (cytosols) prepared routinely according to procedures recom-
mended by the European Organization for Research and Treatment of Cancer
Breast Cancer Cooperative Group with ligand binding assays or enzyme
immunoassays (ER-EIA and PgR-EIA; Abbott Laboratories, IL), as described
previously (20).
Tumor Samples and Patients
To evaluate the clinical significance of TP53 gene alterations in advanced
disease, 265 primary breast tumor specimens were analyzed. Sequence data
(protein coding exons 2–11 of the TP53 gene) were successfully obtained from
243 tumors (92%; Table 1). In five cases, the sequence analysis was incom-
plete, although a mutation was observed; these samples were included. For
nine cases, the sequence analysis was incomplete, but no gene mutation was
observed; these nine samples were not included because mutations could not
be excluded. In 13 cases (5%), no PCR product could be generated (in two
separate experiments). Consequently, the analysis with respect to TP53 muta-
tion and response to systemic therapy was performed on 243 breast cancer
patients who developed recurrent disease. The patient group in the present
study is not identical to the population described previously, i.e., 165 patients
were described previously (5). A total of 202 patients (83%) received first-line
tamoxifen therapy, whereas 41 (17%) patients, especially younger women with
ER-negative tumors, received first-line chemotherapy for advanced disease.
First-Line Tamoxifen Treatment. Between 1979 and 1991, 202 patients
underwent resection of their primary tumors (breast-conserving therapy, 67
patients; modified mastectomy, 132 patients; and biopsy, 3 patients) and were
selected according to the criteria described previously (21). In the first-line
tamoxifen-treated group, 20 patients were stage I, 110 patients were stage II,
45 patients were stage III, and 22 patients were stage IV. With respect to stage,
data on five patients are unknown. Twenty-seven patients (13%) received
systemic adjuvant chemotherapy (CMF, 18 patients; CAF, 9 patients). Twenty-
three patients (11%) were diagnosed with metastatic disease (M1) at the time
of primary surgery. All patients were treated with 40 mg of tamoxifen daily as
a first-line hormonal therapy after relapse. All patients were tamoxifen naı¨ve
and had not received prior chemotherapy for advanced disease. The median
age of these 202 patients at the start of first-line tamoxifen therapy was 62
years (range, 28–85 years). Additional characteristics are listed in Table 2.
The median follow-up of patients who are still alive is 81 months (range,
51–123 months) from primary surgery and 44 months (range, 8–80 months)
from the start of tamoxifen treatment. A total of 163 patients have died (median
survival time, 20 months). Tumor progression occurred in most patients (190
of 202 patients, 94%) during follow-up. Median time to progression was 7.5
months. After tumor progression on first-line tamoxifen treatment, 70% of the
patients were treated with one or more additional endocrine agents (mostly
high-dose progestins), whereas 117 patients were subsequently treated with
one or more regimens of chemotherapy after development of hormone resist-
ance.
First-Line (Up-Front) Chemotherapy. Forty-one patients underwent re-
section of their primary tumors (breast-conserving lumpectomy, 22 patients;
modified mastectomy, 19 patients) between 1983 and 1991. In the up-front
chemotherapy group, 6 patients were stage I, 22 patients were stage II, 9
patients were stage III, and 4 patients were stage IV. After primary surgery, six
patients received adjuvant chemotherapy, and six patients received adjuvant
hormonal therapy. Four patients (10%) were diagnosed with metastasis at the
time of surgery for their primary tumor. As a first-line treatment for advanced
disease, 22 of these 41 patients (54%) received CMF, 16 of 41 patients (39%)
received CAF, 1 of 41 patients received Adriamycin weekly, and 2 of 41
patients received a platinum-containing chemotherapy. The median age at start
of chemotherapy was 50 years (range, 29–74 years). Additional characteristics
are listed in Table 4. Median follow-up was 33 months (range, 5–107 months)
from the date of primary surgery and 12 months (range, 1–75 months) from the
start of chemotherapy for recurrent disease. Tumor progression occurred in all
but one of the patients (98%) during follow-up after the start of chemotherapy.
Median time to progression was 4 months. After 12 months, 19% of the
patients were alive without progression. Response to systemic treatment was
defined by standard Union Internationale Contre le Cancer criteria as a
patient having either CR or PR or prolonged stable disease of more than 6
months (21, 22).
Statistical Methods
The associations of TP53 with continuous variables (ER, PgR, age,
and disease-free interval) were studied with a nonparametric test.
Mutation subsets were analyzed with a Wilcoxon rank-sum test.
Two-sided Ps , 0.05 were considered statistically significant. Logis-
tic regression analysis was used for the analysis of response to
treatment. Cox regression analysis was used for the analysis of time to
treatment failure and overall survival after start of treatment. Survival
curves were generated using the method of Kaplan and Meier (23).
TP53 gene status and the following factors were evaluated in the
multivariate regression analysis: (a) age; (b) menopausal status; (c)
adjuvant therapy; (d) disease-free interval; (e) the dominant site of
relapse (in case of multiple sites, the site with the worst prognosis was
considered dominant); (f) ER; and (g) PgR. TP53 was added to this
model.
Table 1 Patient and tumor characteristics and TP53 mutation
TP53 gene status
No. of patients % mutated P
All patients 243 37
Menopausal statusa
Premenopausal 70 41
Postmenopausal 173 35 0.37
Age (yr)a
,40 25 64
40–55 79 39
55–65 58 29
.65 81 32 0.01c
Dominant site of relapse
Soft tissue 34 50
Bone 115 26
Visceral 94 46 0.003
Disease-free interval (mo)
,12 90 49
.12 153 30 0.003
Prior adjuvant therapy
No 204 35
Yes 39 46 0.20
ER levels (fmol/mg protein)b
,10 63 67
10–75 58 36
.75 121 22 ,0.0001c
PgR levels (fmol/mg protein)b
,10 82 57
10–75 68 35
.75 90 19 0.0001c
a Age and menopausal status at start therapy.
b ER data are missing for one patient, but PgR data are present. PgR data are missing
on three patients for whom ER data are available.
c Test for trend.
2156
TP53 GENE MUTATION AND RESPONSE OF ADVANCED BREAST CANCER
RESULTS
TP53 Gene Mutations. We have sequenced the entire open read-
ing frame of the TP53 gene (exons 2–11). Mutations were detected in
90 of the 243 (37%) samples, 9 of which (10%) were observed outside
the sequence-specific DNA binding domain (codons 102–292). Fifty
of these 90 mutations (56%) were restricted to the conserved region.
Within the zinc-binding domain regions L2 and L3 (residues 163–195
and 236–251, respectively), 31 (34%) mutations were found. More-
over, we observed 15 mutations in four of the seven amino acids
important in direct DNA binding (i.e., codons 241, 248, 273, and 280).
As expected, the majority of the mutations were transitions, and the
amino acid arginine was altered most frequently. Of all 90 mutations,
62 (69%) were missense mutations, including 3 complex mutations
and 1 tandem mutation. In total, these amount to 42 different changes.
The remaining 28 mutations (referred to as non-missense mutations)
were 5 in-frame deletions/insertions, 11 nonsense mutations leading to
a stop codon, and 12 out-of-frame deletions/insertions causing a
premature stop codon. These latter “null mutations” were localized
mainly in exon 6. These results imply that one-fourth of the mutations
detected in this study would not result in an increased expression of
the TP53 protein, i.e., false negatives.
Patient and tumor characteristics are summarized in Table 1. The
prevalence of TP53 gene mutations is highest in tumors from younger
women (,40 years of age), in patients who experienced a shorter
disease-free interval, and in ER- or PgR-negative (,10 fmol/mg
protein) tumors. The median ER levels are about 10 times lower in the
tumors with mutations than in those without a TP53 gene mutation (15
versus 144 fmol/mg protein, respectively). Menopausal status and
prior adjuvant therapy were not significantly related to TP53 gene
mutation. Interestingly, if the primary tumor had a TP53 mutation, the
metastases more often developed in soft tissue (50%) or visceral
tissues (46%) than in bone (26%) as the dominant site of disease. In
an exploratory analysis, we observed a relatively low ratio between
missense and nonmissense mutations in the primary tumor of patients
who developed a relapse in soft tissue (ratio, 1.4) when compared with
the ratios in patients who relapsed to bone or visceral tissues (ratios,
3 and 3.5, respectively) as the first site of relapse.
TP53 Gene Mutations and Response to Tamoxifen. We ob-
served a mutation in 65 of 202 (32%) primary tumor samples, and
this resulted in a premature termination of the protein in 13 of these
65 samples (20%). Of the 202 patients, 55% responded to first-line
tamoxifen therapy (10 CRs, 25 PRs, and 76 cases of stable dis-
ease). Very young patients (,40 years) tended to have a lower
response rate (33%; Table 2). Furthermore, the presence of bone or
visceral metastasis, a short disease-free interval after primary
surgery, and low ER and PgR levels were significantly associated
with low response rates to tamoxifen, whereas prior adjuvant
therapy showed no relation with response (Table 2). Sixty-six
percent of the patients without a TP53 mutation responded to
tamoxifen, whereas only 31% of the patients with a TP53 mutation
responded to tamoxifen therapy (OR, 0.22; P , 0.0001; Table 2).
There was no significant difference between the response percent-
ages of either missense or nonmissense mutations (29% and 38%,
respectively). The TP53 gene mutations were stratified according
to the type of mutation, i.e., mutations in the zinc-binding domains
L2 and L3 of the protein, or by residues that directly contact DNA
in an exploratory analysis. Five of 12 (42%) patients with muta-
tions in L2 but only 2 of 13 (15%) patients with mutations in L3
or 2 of 11 (18%) patients with mutations in codons that directly
contact DNA showed a response compared to a response of 66% in
patients with a wild-type TP53 gene.
Multivariate Analysis for Response to Tamoxifen. The inde-
pendent relationship of the variables with response to tamoxifen
therapy for advanced disease was studied using multivariate logistic
Table 2 Patient and tumor characteristics and response rate to first-line tamoxifen therapy of recurrent disease
No. of
patients
Response
rate (%)
Univariate Multivariate
Survival after start
of therapy (median)P OR CI P OR CI
All patients 202 55 24 mo
Menopausal status
Premenopausal 47 45 1 1 30 mo
Postmenopausal 155 58 0.11 1.71 0.89–3.31 0.67 1.28 0.41–4.01 23 mo
Age (yr)a
,40 15 33 1 1 18 mo
40–55 61 51 2.07 0.63–6.76 1.33 0.31–5.68 29 mo
55–65 51 57 2.64 0.79–8.82 1.44 0.24–8.78 25 mo
.65 75 61 0.21 3.17 0.98–10.22 0.55 2.47 0.41–15.01 20 mo
Dominant site of relapse
Soft tissue 24 79 1 1 28 mo
Bone 105 53 0.30 0.10–0.87 0.12 0.03–0.44 28 mo
Visceral 73 49 0.03 0.26 0.09–0.76 0.001 0.11 0.03–0.43 19 mo
Disease-free interval (mo)
,12 70 37 1 1 18 mo
.12 132 64 0.0002 3.06 1.68–5.59 0.0027 2.95 1.44–6.07 29 mo
Prior adjuvant therapy
No 175 54 1 1 24 mo
Yes 27 59 0.63 1.22 0.54–2.79 0.23 1.95 0.65–5.84 25 mo
ER levels (fmol/mg protein)b
,10 37 30 1 1 1 1 16 mo
10–75 47 47 2.08 0.84–5.16 1.84 0.57–5.92 23 mo
.75 117 66 0.00025 4.55 2.04–10.14 0.03 3.82 1.27–11.51 30 mo
PgR levels (fmol/mg protein)b
,10 53 43 1 1 1 1 19 mo
10–75 61 48 1.18 0.56–2.48 0.70 0.27–1.82 21 mo
.75 85 68 0.0054 2.80 1.38–5.70 0.28 1.33 0.52–3.41 36 mo
TP53 gene status
Wild-type 137 66 1 1 29 mo
Mutated 65 31 <0.0001 0.22 0.12–0.42 0.0014 0.29c 0.13–0.63 20 mo
a Age (years) at the time of the primary tumor.
b ER information on one patient and PgR information for three patients are missing.
c The increment in x2 is 10.2. Significant data are shown in bold.
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Fig. 1. PFS (left) and survival after the start of tamoxifen treatment (right) as a function of TP53 gene status in all patients (ALL), patients with high ER (.75 fmol/mg protein;
ER-high), patients with intermediate ER (10 . ER ,75 fmol/mg protein; ER-medium), and patients with low ER (,10 fmol/mg protein; ER-low). The number of patients below the
X axis represents the number at risk over total patients in the wild-type and mutated subgroups, respectively.
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regression analysis. TP53 gene mutation status (as a dichotomized
variable) was added to the classical variables (see Table 2). Disease-
free interval, dominant site of relapse, and ER and TP53 status were
significant in this multivariate analysis. There was no statistically
significant interaction between TP53 mutation and ER levels.
Response in Clinically Relevant Subsets of Patients Stratified
by ER and PgR Status. We explored the association of TP53 gene
status with response to tamoxifen therapy in clinically relevant sub-
groups. Subsets of tumors from patients with low ER levels (,10
fmol/mg protein, median survival of the patients 5 16 months; see
Table 2), intermediate ER levels ($10 fmol/mg protein but ,75
fmol/mg protein, median survival of the patients 5 23 months), and
high ER levels (.75 fmol/mg protein, median survival of the pa-
tients 5 30 months) were created. In all three subgroups, according to
ER status, the response rate was better in patients with wild-type TP53
in their primary tumors. The worst overall response was observed in
patients with ER-negative and TP53-mutated tumors (n 5 23), of
whom only 22% responded. The best response was observed in the
patients with high ER levels and wild-type TP53 in their primary
tumors (n 5 90), of whom 73% responded.
Relationship Between P53 Mutation and PFS after the Start of
Treatment. Duration of response is perhaps as important as time to
treatment failure because the duration of response contributes directly
to the quality and duration of life. Using Cox univariate regression
analysis, we observed that the presence of a TP53 gene mutation was
significantly associated with a shorter duration of response (16 versus
11 months; P 5 0.0006) in 111 patients who responded to tamoxifen.
However, TP53 mutation was not significantly associated with
survival after the start of treatment (40 versus 31 months) in the
responders.
The median PFS was shorter for patients with a TP53 mutation as
compared with those with wild-type TP53 (3.0 versus 9.6 months).
Patients with TP53 gene mutation in their primary tumors experienced
a shorter PFS and an earlier death (relative hazard rate, 2.61 and 1.99,
respectively, both P , 0.001) than those with TP53 wild-type tumors
(see Fig. 1, ALL). In addition (see Table 2), younger patients
(age , 40 years) and those with visceral metastasis, a short disease-
free interval, low ER or PgR levels, or TP53 mutation showed a
shorter median overall postrelapse survival after the start of tamoxifen
treatment. In the multivariate analysis for survival after the start of
tamoxifen treatment, the presence of a TP53 mutation was associated
with decreased survival (RHR, 1.39; 95% CI, 0.94–2.07; P 5 0.10).
We next explored the predictive value of TP53 mutations in sub-
groups with low, intermediate, and high ER levels. The relationship
between TP53 status and PFS and overall survival after the start of
treatment was most apparent in the high ER and intermediate ER (Fig.
1, ER-medium) subsets of patients but absent in the ER-negative
subset (Fig. 1, bottom panels).
TP53 Gene Mutations and Response to Chemotherapy. Of the
113 patients that were evaluable for chemotherapy after tamoxifen
therapy in this study, 51 (45%) responded to chemotherapy (1 CR, 19
PRs, and 31 cases of stable disease). When compared with bone
metastasis and soft tissue, patients with visceral metastasis had the
worst response to chemotherapy after tamoxifen treatment (OR, 0.66).
As shown in Table 3, patients with TP53 mutations did not respond
differently to chemotherapy after tamoxifen therapy than did patients
without mutations. Stratification according to domain L3 of the pro-
tein or by residues that directly contact DNA (see above) revealed that
three of five patients with mutations in L3 and two of seven patients
with mutations in codons that directly contact DNA showed a re-
sponse when compared with an overall response of 42% of patients
with the wild-type TP53 gene.
Of the 41 patients studied with respect to up-front (first-line)
chemotherapy, 19 (46%) responded (4 CRs, 11 PRs, and 4 cases of
stable disease). A relatively high prevalence (61%) of TP53 gene
mutation was observed, i.e., TP53 gene mutation was observed in 25
Table 3 Patient and tumor characteristics and response to chemotherapy of patients with recurrent disease
No. of
patients
Up-front chemotherapy
No. of
patients
Chemotherapy after tamoxifen
Response Univariate Response Univariate
(%) P OR 95% CI (%) P OR 95% CI
All patients 41 46 113 45
Menopausal status
Premenopausal 23 61 1 29 48 1
Postmenopausal 18 28 0.03 0.25 0.07–0.93 84 44 0.69 0.84 0.36–1.97
Age (yr)
,40 10 50 1 10 50 1
40–55 18 56 1.25 0.27–5.89 39 49 0.95 0.24–3.81
55–65 7 43 0.75 0.11–5.24 34 47 0.89 0.22–3.64
.65 6 17 0.38 0.20 0.02–2.39 30 37 0.75 0.58 0.14–2.46
Dominant site of relapse
Soft tissue 10 40 1 4a 50 1
Bone 10 60 2.25 0.38–13.47 46 52 1.09 0.14–8.42
Visceral 21 43 0.60 1.13 0.24–5.21 63 40 0.42 0.66 0.09–4.98
Disease-free interval (mo)
,12 20 55 1 39 44 1
.12 21 38 0.28 0.50 0.14–1.75 74 46 0.81 1.10 0.50–2.40
Prior adjuvant therapy
No 29 48 1 96 45 1
Yes 12 42 0.70 0.77 0.20–2.98 17 47 0.86 1.10 0.39–3.08
ER levels (fmol/mg protein)
,10 26 46 1 21 43 1
10–75 11 55 1.40 0.34–5.76 31 45 1.10 0.36–3.35
.75 4 25 0.59 0.39 0.04–4.25 60 47 0.95 1.17 0.43–3.18
PgR levels (fmol/mg protein)
,10 29 48 1 29 41 1
10–75 7 43 0.80 0.15–4.25 40 43 1.05 0.40–2.76
.75 5 40 0.92 0.71 0.10–4.93 42 50 0.71 1.42 0.55–3.68
TP53 gene status
Wild type 16 63 1 73 42 1
Mutated 25 36 0.10 0.34 0.09–1.24 40 50 0.44 1.35 0.62–2.94
a Dominant site of relapse at start of chemotherapy after tamoxifen treatment. Significant data are shown in bold.
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of 41 primary tumors. In 10 of these 25 samples (40%), this resulted
in a premature termination of the protein. As shown in Table 3, only
36% percent of the 25 patients with a TP53 mutation responded to
first-line chemotherapy, in contrast to 63% of the 16 patients without
a TP53 mutation (OR, 0.34). In this exploratory study on a small
number of patients, only menopausal status was significantly corre-
lated with response to up-front chemotherapy; none of the other
patient and tumor characteristics studied were significantly correlated
with response to up-front chemotherapy. The median PFS was 3.0
months for those patients with TP53-mutated tumors versus 3.6
months for patients without TP53 mutation.
DISCUSSION
The onset and progression of breast cancer is accompanied by
multiple genetic alterations that result in quantitative and qualitative
changes in the expression of these genes. Mutations in the TP53 gene
are the most frequent genetic changes in human cancer, and, depend-
ing on the method of detection, the frequencies of TP53 mutations
reported in invasive breast cancer range from 12–46% (24). In recent
years, numerous reports have appeared on the relation between TP53
status and (disease-free) survival, and conflicting conclusions were
reached on the prognostic value of TP53 in breast cancer. The lack of
unanimity between authors may be explained by: (a) differences in
techniques used for the analyses of p53 status (e.g., immunohisto-
chemical analyses with different antibodies on frozen or paraffin-
embedded tissues using different cutoff levels, ELISA/LIA, PCR-
single-strand conformational polymorphism/constant denaturing gel
electrophoresis analyses of primarily exons 5–8, or cDNA sequencing
of the entire gene); (b) patient sample size; (c) subset analyses; (d)
retrospective nature of the studies; (e) different (adjuvant) treatments
of the patient population; (f) different (modern) prognostic covariates
used in the multivariate analyses; (g) the subjectivity inherent to some
approaches; and (h) publication bias.
Moreover, the relapse tumor could be dissimilar to the primary
tumor because it was shown that TP53 mutations found in the primary
tumors can be absent in the metastasis.
In the present study, we evaluated the predictive value of TP53
gene mutations, as estimated through cDNA sequencing of the entire
coding sequence of the TP53 gene, in a relatively large series of breast
cancer patients who were treated with tamoxifen or chemotherapy for
advanced disease. We observed TP53 gene mutations in 32% of the
202 primary tumors of tamoxifen-treated patients and in 61% of the
41 patients (with mainly ER-negative tumors) treated with up-front
chemotherapy. The observed prevalence is slightly higher than the
mean percentage of 25% [range, 15–71%; examined in 1425 breast
tumor samples worldwide; reviewed by Hartmann et al. (25)] and a
prevalence of 29% [range, 15–71%; examined in 16 populations by
Soussi (26)]. This difference can be explained by the fact that the
entire coding sequence of TP53 was investigated and that only those
patients who developed advanced disease were included in the present
study. TP53 gene mutation was related with a poor response to
up-front chemotherapy in our small series of patients (OR, 0.34) and
was similarly but significantly related with a poor response to first-
line tamoxifen treatment in both univariate analysis (OR, 0.22;
P , 0.0001) and multivariate analysis. In contrast, patients with
mutated TP53 in their primary tumors may respond better to chemo-
therapy (50% versus 42%) after tamoxifen treatment, but they did
show a shorter PFS and duration of response.
When evaluating only those reports that have covered TP53 alter-
ations in relationship with the efficacy of various treatments in breast
cancer, we noticed that there is no agreement on the significance of
the predictive value of TP53. The summary of these 26 studies on
almost 6000 breast cancer patients is listed in Table 4. In 15 reports,
there was no significant relation between TP53 status and type of
response (2, 3, 6–12, 15, 28, 30–33), 7 reports described resistance
(Refs. 5, 6, 14, 16, 27 and 29 and this study), whereas the other 4
Table 4 Predictive relevance of TP53 in breast cancer
Author Year No. Stage of disease Technique % abnormal Treatment Predictive
Endocrine therapy 1435
Bergh 1995 298 Primary cDNA sequencing 22% Adjuvant TAMa and RT Resistant
Archer 1995 92 Advanced IHC 58% Hormonal No
Silvestrini 1996 240 Primary IHC 14% Adjuvant TAM Resistant
Elledge 1997 202 Metastatic IHC 20% TAM No
Berns 1998 401 Metastatic LIA Median TAM Resistant
Berns 2000 202 Metastatic cDNA sequencing 32% TAM Resistant
(this study)
Chemoendocrine therapy 341
Elledge 1995 261 Primary IHC 38% Adjuvant chemo (CMF & prednisone) No
Markris 1997 80 Primary IHC 39% Neoadjuvant chemo and TAM No
Chemo 3428
Jacquemier 1994 81 Primary IHC 39% Adjuvant chemo No
Faille 1994 38 Loc advanced PCR-SSCP sequencing 36% Chemo Resistant
Muss 1994 394 Primary IHC 35% Adjuvant chemo No
Stål 1995 139 Primary IHC 14% Adjuvant chemo Sensitive
Aas 1996 63 Loc advanced IHC ??? Doxorubicin monotherapy No
Aas 1996 63 Loc advanced CDGE/cDNA sequencing 29% Doxorubicin monotherapy Resistant
MacGrogan 1996 125 Primary IHC 27% Neoadjuvant chemo No
Linn 1997 70 Primary IHC 65%/30% Neoadjuvant chemo high dose & GM-CSF No
Dublin 1997 277 Primary IHC 21% Adjuvant CMF No
Niskanen 1997 103 Metastatic IHC 16% FEC No
Bonetti 1998 43 Metastatic IHC 51% CMF/CA-EF No
Rozan 1998 329 Primary IHC 38% Neoadjuvant chemo No
Degeorges 1998 277 Primary IHC 24% Adjuvant chemo No
Clahsen 1998 440 Primary IHC 18% FAC, one course perioperative Resistant
Ja¨rvinen 1998 55 Advanced IHC 33% Epirubicin monotherapy No
Thor 1998 994 Primary IHC 33% Adjuvant CAF dose intensive Sensitive
Radiotherapy 781
Jansson 1995 168 Primary cDNA-based sequence 18% Adjuvant locoregional RT Sensitive
Silvestrini 1997 613 Primary IHC 18% Adjuvant RT Sensitive
a TAM, tamoxifen; RT, radiotherapy; chemo, chemotherapy; GM-CSF, granulocyte macrophage colony-stimulating factor; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide;
CA-EF, cyclophosphamide Adriamycin-epirubicin 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; Loc, local; SSCP, single strand conformational polymor-
phism; CDGE, constant denaturing gel electrophoresis.
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studies reported sensitivity (13, 34–36). However, this survey indi-
cates that the TP53 genotype, not the immunohistochemical results, is
predictive of response in breast cancer patients: all 5 studies that used
DNA analysis showed a predictive value of TP53, whereas this was
only true in 6 of the 21 immunohistochemical studies, i.e., 2 studies
showed sensitivity, and 4 showed resistance. Both studies on radio-
therapy showed sensitivity to this form of treatment (34, 36).
The mechanisms that underlie the relationship of p53 alterations
and a poor response to tamoxifen are not clear. Tamoxifen acts as an
antiestrogen via the ER, but some of its effects are thought to be
mediated through the activation of transforming growth factor b and
by decreasing plasma insulin-like growth factor I levels. Previous data
suggest that the mutant forms of TP53 inhibit the antiproliferative
effect of transforming growth factor b by interfering with its signaling
pathway. In addition, wild-type TP53 can repress the insulin receptor
and the insulin-like growth factor I receptor promotor in other cell
types. Although the exact mechanisms are unclear, this complex
interplay provides a link between the TP53 gene and signaling path-
ways in breast cancer cells (discussed in Ref. 5). Our finding on the
relationship between TP53 gene mutation and poor response to ta-
moxifen treatment of advanced disease is well in line with our
previous study on p53 protein levels by LIA in 401 patients with
advanced disease (5) but disagrees with the studies of Archer et al. (2)
and Elledge et al. (3), who assessed p53 expression immunohisto-
chemically and found no relationship with response to endocrine
treatment. Bergh et al. (14) and Silvestrini et al. (32) showed that
tamoxifen also appears to be of less benefit in patients with TP53 gene
mutations or overexpression, respectively, in the adjuvant setting (see
Table 4). The relationship of TP53 gene status with PFS is most
apparent in the high ER (.10 fmol/mg protein) subgroups of our
patients. In contrast to our findings, Elledge et al. (3), who studied the
accumulation of p53 using IHC in mainly ER-positive metastatic
breast cancer, did not observe a relation between p53 status and
response to tamoxifen therapy, although they stated that breast tumors
with altered p53 protein are inherently more aggressive, even after
they have metastasized. These conflicting outcomes may again be
explained by the different techniques and study designs.
It is known that some chemotherapeutic agents and ionizing radi-
ation act by inducing apoptosis in tumor cells. Lowe et al. (37)
showed that cells expressing mutant TP53 were totally resistant to
apoptosis on treatment, whereas cells expressing the wild-type gene
were sensitive to these therapeutic agents. In the present study, TP53
gene mutations were related, although not significantly, to a poor
response to up-front chemotherapy (36% versus 63%; OR, 0.34).
However, the number of patients receiving first-line chemotherapy
was small, the regimen is heterogeneous, and the follow-up was
relatively short. Based on this, it is not possible to draw firm conclu-
sions. Furthermore, we suspect a better response to chemotherapy
after tamoxifen treatment.
Three reported molecular analyses also revealed that TP53 gene
mutations predict a response to chemotherapy or adjuvant radiother-
apy in breast cancer patients (6, 33, 35). In contrast, all 4 reports on
metastatic disease and 7 of 10 reports in the adjuvant setting revealed
no predictive value of TP53 when using immunohistochemical anal-
yses.
Various mutations can alter the TP53 protein distinctly and lead to
different biological characteristics and tumorigenic potential (38, 39).
L2 and L3 loops of the TP53 gene contain residues involved in direct
DNA contact as well as protein stabilization. In the present study,
those patients with TP53 gene mutations in codons that directly
contact DNA or with mutations in the zinc-binding domain loop L3
showed the lowest response to tamoxifen (18% and 15% response
rates, respectively). Survival analyses showed a significantly reduced
survival rate for patients with mutations affecting the zinc-binding
domains L2 and L3 compared with patients with mutations outside
these regions or with no mutations (40) or for patients with mutations
affecting the direct DNA contact (41). Moreover, Aas et al. (6)
showed that mutants affecting the L3 loop were significantly associ-
ated with de novo resistance to doxorubicin monotherapy in small
subsets of patients. Extending the analysis of these various mutations
allows us to focus attention on the biological significance of particular
mutations that may assist the selection of residues that could be of
predictive value in breast cancer.
IHC is not able to detect every TP53 alteration. In the present study,
we have shown that one-fourth of TP53 mutations found are “null
mutations” that do not lead to TP53 accumulation. Furthermore, IHC
does not us allow to distinguish the heterogeneity of TP53 mutants.
Based on the data from the literature and the present results, we
conclude that the presence of mutation and the type of mutation have
predictive value for response to tamoxifen treatment. Therefore, we
reason that, if tissue resources permit, the TP53 mutation status should
preferably be included in the daily practice of treatment of metastatic
breast cancer patients.
The main conclusion of this study is that TP53 mutation is signif-
icantly associated with a poor response to tamoxifen treatment in
patients with advanced breast cancer. Based on the present results and
the data reviewed, it is tempting to hypothesize that the TP53 geno-
type in particular and, to a lesser degree, the immunohistochemical
analysis are predictive of response to therapy in breast cancer. Pro-
spective studies should be performed to support this conclusion.
Besides mutation analyses, a direct functional assay (42) or the
measurement of downstream components of the TP53 pathway such
as p21 or MDM2 may confirm the TP53 integrity.
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